|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||287.84 - 293.51|
|52-week range||287.84 - 293.51|
|Beta (5Y monthly)||0.45|
|PE ratio (TTM)||0.31|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.
Several biotech stocks have outperformed the struggling market this year. This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL), and Amgen (NASDAQ: AMGN). Let's consider why these three biotechs are solid buys for the next decade.
Between rumors of a recession, rising interest rates, and inflation, it's tough to find stocks that you're confident will keep growing instead of going to zero. Vertex Pharmaceuticals (NASDAQ: VRTX) is worth a $2,500 investment because it's the world's largest public business devoted to curing rare diseases, and it's proven to be quite adept at that goal so far.